Thank you, Mr. Chairman and members of the committee.
I'm here representing BIOTECanada as a director on the board and its past chairman.
You have an information package in the folder that was provided to you. I'm going to go through my presentation with some highlights of information relevant to the slides that you have. More details are on the slides as well as in the formal submission that was made to committee this August.
BIOTECanada represents a large body of the biotechnology industry in Canada. This is an industry that, I want to expound here, is in distress at the moment. What they ask the committee to consider in the budget for 2010 is, in three quick points: to address the cash crunch through a loan program; to sustain a vaccine funding program, which is already in place but needs renewal; and to grow the SD Tech Fund, the sustainable technologies fund administered by SDTC. The amounts are as listed there.
The primary reason for this, as I said, is that the industry is in distress at the moment, but the second and major reason is that the return on investment for past government investment is at high risk of being lost unless those actions are taken.
The industry is not a small or a new industry in Canada; it's a significant one. Industry contributes over $78 billion in GDP to Canada's economy on an annual basis. It's really of roughly the same size as the oil and gas sector and the automotive sector, yet it's an industry that has frankly very little profile in a consolidated industry setting; let's put it that way. It's an industry that is fractionated; this next slide shows you that. It's composed of therapeutics, ag-bio, industrial, and so forth. The pie chart shows the distribution. The growth sectors for it are in the ag-bio, industrial, and environmental areas, the very things government is wanting and needing to promote in Canada.
A quick word about the vaccines component, because it's really quite specific. The vaccines support—the $100 million that has been provided by government regularly—has had a major impact on the health of Canadians and on the reduction of overall health costs in the country. We are firmly convinced that the same rewards will be gained by the country at large through continuing that program. As we all know when we read about H1N1, which is a viral disease, and others is that infectious diseases are an issue in the country.
The general Canadian public is not uninformed about the importance of science and technology. The question was asked whether people had concern about the global competitiveness of our country in science and technology. Certainly the majority of the general population, as shown on slide 5, feels that this is something very important to them. When you get a little more specific and ask, as we did in this year's Nanos survey, whether or not biotechnology has a contribution to make to that future prosperity, 90%-plus of individuals contacted in Canada feel that biotechnology makes a major contribution to the overall future expectations of the country.
Then what is the problem? The industry is in trouble because by definition this industry has an ongoing need for capital. It goes through capital financing cycles, and those financing cycles are dead at the moment. In particular, those that are affected are, as shown on this slide, the emerging companies of Canada, those at the cusp of making a major value increment to the country. It is simple, and there are more details here showing you that venture financing, market capitalization—the traditional sources of capital for the biotechnology industry—have become fragmented, have decreased, or are no longer available.
One might say let the chips fall where they may, but if we don't recognize our ROI from R and D investments in the country, the industry will not be sustainable. It is leaving the country as it is. There is an attrition happening at a very rapid rate, and at the same time we seem to be seeing the biotechnology industry, in future years at least, as less and less competitive. In other countries with which we compete, that is not the scenario. They are increasingly funding biotechnology advances and are making a very strong and concerted effort to support that industry within their own country.
We'll slip to the details on the last slide.
These global initiatives in the economic platforms of the U.S., Australia, China, India, Taiwan, and on and on are having a major impact now on growing that industry in those countries for future expectations. As an industry association, we feel that it is a major loss. Basically, every month that passes it's a major loss. If we go a year or two, into next year, there's a very high probability that biotechnology in this country will become second-rate rather than the first-rate it is right now.
Thank you.